

Supplemental Figure 1. T cells with conditional ablation of SLP-76 do not upregulate CD69 upon TCR stimulation. (A) SLP-$76^{F/+}$ or SLP-$76^{F/-}$ mice crossed to ER-Cre and a ROSA26-STOP-flox-YFP reporter were treated with Tamoxifen orally for 5 days followed by a 7 day rest period. YFP^{+} Tregs were sorted on Day 12 for suppression experiments. (B) On Day 11, YFP^{+} T cells from the peripheral the blood of Tamoxifen-treated mice were stimulated with anti-CD3 for 18 hours and stained for CD69 expression.



Supplemental Figure 2. The loss of SLP-76 in Tregs variably changes effector/differentiation marker expression. SLP-76$^{+/+}$, SLP-76$^{F/+}$, or SLP-76$^{F/–}$ mice crossed to ER-Cre and a ROSA26-STOP-flox-YFP reporter were treated with Tamoxifen orally for 5 days followed by a 7 day rest period. On Day 12, the expression of GITR, CTLA4, CD25, ICOS, CD39, KLRG1, CD103, CD69, CXCR3, and CD62L was examined on YFP^{+}CD4^{+}Foxp3^{+} cells as indicated. One representative of two independent experiments is shown.



Supplemental Figure 3. The loss of DGKζ in Tregs minimally affects the expression of effector/differentiation markers. DGKζ$^{+/+}$ or DGKζ$^{F/F}$ mice crossed to ER-Cre and a ROSA26-STOP-flox-YFP reporter were treated with Tamoxifen orally for 5 days followed by a 7 day rest period. On Day 12, the expression of GITR, CTLA4, CD25, ICOS, CD39, KLRG1, CD103, CD62L, CD69, and CXCR3 was examined on YFP^{+}CD4^{+}Foxp3^{+} cells as indicated. One representative of two independent experiments is shown.

.